Related Experiment Video
Updated: Jun 4, 2026
Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
[Comparison of EGFR mutation status in paired pre- and post-chemotherapy serum for advanced pulmonary adenocarcinoma]
Rubing Han1, Wei Zhong, Jing Zhao
1Department of Respiratory Disease, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing 100730, China.
Background And Objective:
Non-small cell lung cancer (NSCLC) with mutations in the epidermal growth factor receptor (EGFR) is a distinct subgroup of NSCLC, which is particularly responsive to EGFR tyrosine kinase inhibitors (TKIs). The aim of this study is to detect EGFR mutations in paired serum of pre- and post-chemotherapy from advanced pulmonary adenocarcinoma patients to evaluate impact of chemotherapy on EGFR mutation status.
Methods:
Magnetic beads were used for DNA extraction from paired serum of pre- and post-chemotherapy of 33 advanced pulmonary adenocarcinoma patients. The EGFR exon 19 and 21 were amplified by mutant-enriched nested PCR and analyzed by direct sequencing.
Results:
EGFR mutations were detected in 39.4% (13/33) and 54.5% (18/33) serum samples of pre- and postchemotherapy, respectively. The EGFR mutation status was consistent in 54.5% (18/33) patients. Among 15 discordant cases, 10 changed from pre-chemo wild-type to post-chemo mutant-type status, while 5 from pre-chemo mutant-type to post-chemo wild-type status.
Conclusions:
Chemotherapy may have influence on serum EGFR mutation status in advanced adenocarcinoma patients.
Insights
Chemotherapy may alter epidermal growth factor receptor (EGFR) mutation status in advanced lung adenocarcinoma patients. This study observed changes in EGFR mutations in serum DNA before and after chemotherapy treatment.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Non-small cell lung cancer (NSCLC) with EGFR mutations is sensitive to EGFR tyrosine kinase inhibitors (TKIs).
- EGFR mutation status in serum is a potential biomarker for NSCLC treatment.
Purpose of the Study:
- To investigate the impact of chemotherapy on EGFR mutation status in advanced pulmonary adenocarcinoma patients.
- To analyze paired serum samples collected before and after chemotherapy.
Main Methods:
- DNA extraction from serum using magnetic beads.
- EGFR exons 19 and 21 amplification via mutant-enriched nested PCR.
- Direct sequencing for EGFR mutation analysis.
Main Results:
- EGFR mutations were detected in 39.4% of pre-chemotherapy and 54.5% of post-chemotherapy serum samples.
- Concordant EGFR mutation status was observed in 54.5% of patients.
- 10 patients showed a shift from wild-type to mutant, and 5 from mutant to wild-type post-chemotherapy.
Conclusions:
- Chemotherapy may influence the detectable EGFR mutation status in serum.
- Changes in serum EGFR mutations warrant further investigation in advanced adenocarcinoma.